Induction of Multiple Sclerosis and Response to Tyrosine Kinase Inhibitors-Reference-Cited by-同舟云学术

Induction of Multiple Sclerosis and Response to Tyrosine Kinase Inhibitors

Published:2013-09-28 Issue:4 Volume:29 Page:491-495
ISSN:0970-1915
Container-title:Indian Journal of Clinical Biochemistry
language:en
Short-container-title:Ind J Clin Biochem

Author:

Moawad Emad Y.

Publisher

Springer Science and Business Media LLC

Subject

Clinical Biochemistry

Link

http://link.springer.com/content/pdf/10.1007/s12291-013-0387-z.pdf

Reference20 articles.

1. Steinman L. Multiple sclerosis: a two-stage disease. Nat Immunol. 2001;2:762–4.

2. Herndon RM. The pathology of multiple sclerosis. In: Herndon RM, editor. Multiple sclerosis: immunology, pathology and pathophysiology. New York: Demos Medical Publishing; 2003. p. 185–97.

3. Benveniste E. Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis. J Mol Med. 1997;75(3):165–73.

4. Vos CM, van Haastert ES, de Groot CJ, van der Valk P, de Vries HE. Matrix metalloproteinase-12 is expressed in phagocytotic macrophages in active multiple sclerosis lesions. J Neuroimmunol. 2003;138:106–14.

5. Sayed BA, Christy AL, Walker ME, Brown MA. Meningeal mast cells affect early T cell central nervous system infiltration and blood-brain barrier integrity through TNF: a role for neutrophil recruitment? J Immunol. 2010;184(12):6891–900.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Repositioning of receptor tyrosine kinase inhibitors;Receptor Tyrosine Kinases in Neurodegenerative and Psychiatric Disorders;2023

2. FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders;Pharmaceuticals;2022-12-13

3. Non-receptor tyrosine kinase signaling in autoimmunity and therapeutic implications;Pharmacology & Therapeutics;2019-09

4. Expanding spectrum of anticancer drug, imatinib, in the disorders affecting brain and spinal cord;Pharmacological Research;2019-05

5. Data to establish the optimal standard regimen and predicting the response to docetaxel therapy;Data in Brief;2015-12